Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is protected by 3 US drug patents filed in 2013. Out of these, 1 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humalog Kwikpen's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humalog Kwikpen's patents.

FDA has granted several exclusivities to Humalog Kwikpen. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Humalog Kwikpen, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Humalog Kwikpen.

US patents provide insights into the exclusivity only within the United States, but Humalog Kwikpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humalog Kwikpen's family patents as well as insights into ongoing legal events on those patents.

Generic Launch

About Humalog Kwikpen

Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia. Humalog Kwikpen uses Insulin Lispro Recombinant as an active ingredient. Humalog Kwikpen was launched by Lilly in 2019.

Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is protected by 3 US drug patents filed in 2015. Out of these, 1 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humalog Kwikpen's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humalog Kwikpen's patents.

US patents provide insights into the exclusivity only within the United States, but Humalog Kwikpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humalog Kwikpen's family patents as well as insights into ongoing legal events on those patents.

Generic Launch

About Humalog Kwikpen

Humalog Kwikpen is a drug owned by Eli Lilly And Co. It is used for managing diabetes, irritable bowel syndrome with diarrhea, and hyperglycemia. Humalog Kwikpen uses Insulin Lispro Recombinant as an active ingredient. Humalog Kwikpen was launched by Eli Lilly And Co in 2015.